Deals: Page 64
-
Former Dendreon CEO leads Alpine Immune to $48 million financing
While at Dendreon, Mitch Gold oversaw development of the cancer cell therapy Provenge, which failed to live up to expectations following approval in 2010.
By Ned Pagliarulo • June 14, 2016 -
Dr. Reddy's snaps up eight generics from Teva for $350 million
Teva is divesting assets in order to win U.S. approval for its $40.5 billion acquisition of Allergan's generics business.
By Nicole Gray • June 14, 2016 -
Walgreens kills Theranos partnership, will close blood testing centers
The drugstore chain's decision is another huge blow to the controversial blood testing company.
By Randy Lilleston • June 13, 2016 -
Valeant weighs sale of Egyptian drug company
Last year, Valeant acquired Amoun Pharmaceuticals for $800 million via purchase of Mercury Holdings.
By Nicole Gray • June 13, 2016 -
Montgomery County Planning Commission
Merck acquires Afferent for $500M plus milestones
The deal gives Merck access to two promising treatments for chronic cough.
By Randy Lilleston • June 13, 2016 -
Report: Oncology drove record pharma dealmaking in 2015
Records were set last year for venture funding raised for drug companies, as well as upfront dollar value of licensing deals for R&D-stage assets, according to the new report.
By Ned Pagliarulo • June 9, 2016 -
Courtesy of Sanofi
Sanofi boosts takeover pressure, names Medivation board candidates
The move, if successful, would put in place a board that would be friendly to purchase by Sanofi, which Medivation so far has resisted.
By Randy Lilleston • June 9, 2016 -
AstraZeneca continues to shed rights to gout drug
Germany-based Grünenthal will pay up to $230 million for European and Latin American rights to Zurampic, a month after AstraZeneca sold U.S. rights to Ironwood.
By Nicole Gray • June 3, 2016 -
Swiss biotech AC Immune readies US IPO
Regulatory filings indicated the company hopes to raise up to $50 million, which it plans to use to advance its Alzheimer's drug.
By Nicole Gray • June 2, 2016 -
Two San Diego biotechs merge to create new oncology-focused company
Oncternal Therapeutics and Tokalas aim to advance two early-stage cancer drugs.
By Nicole Gray • June 2, 2016 -
Report: Investors concerned Teva overpaid for Allergan generics unit
Teva is currently working to win U.S. approval for its $41 billion deal, which cleared regulatory review in Europe earlier this year.
By Nicole Gray • June 2, 2016 -
Intercept shares climb on FDA approval of liver drug
Ocaliva, or obeticholic acid, is the first new treatment for primary biliary cholangitis to reach the market in nearly 20 years.
By Ned Pagliarulo • May 31, 2016 -
Wellcome Trust scores with startup investment in diagnostic company
Blue Earth Diagnostics, which is owned by the investment arm of Wellcome Trust, received FDA approval for a cancer diagnostic last Friday.
By Nicole Gray • May 31, 2016 -
Jazz Pharma snaps up leukemia drug with $1.5 billion deal for Celator
The $30.25 price per share is roughly double Celator's closing price last Friday.
By Ned Pagliarulo • May 31, 2016 -
Contract researcher BioClinica reportedly weighing sale
The CRO market has been consolidating with major mergers announced or rumored over the past year.
By Nicole Gray • May 27, 2016 -
Fate of Ionis drug in doubt after GSK decides against Phase 3 study
The FDA had placed a clinical hold on the rare disease drug in April.
By Nicole Gray • May 27, 2016 -
Novartis moves toward sale of $14 billion stake in Roche
Challenges at Novartis' eye-care unit Alcon, along with slow sales for Entresto, have put pressure on the company.
By Nicole Gray • May 26, 2016 -
Courtesy of Sanofi
Sanofi goes after Medivation's board as takeover battle heats up
The current board would be replaced with eight directors hand-picked by Sanofi if the move is successful.
By Randy Lilleston • May 25, 2016 -
Arbor Pharma buys XenoPort for $467 million
Known for its restless leg syndrome treatment, XenoPort has fallen on hard times in the past year.
By Nicole Gray • May 24, 2016 -
Janssen ponies up $740 million for another MacroGenics cancer drug
Under the terms of the deal, Janssen will pay MacroGenics $75 million up front, with $665 million in potential milestone payments.
By Nicole Gray • May 19, 2016 -
Celgene expands partnership with Agios into immuno-oncology
Agios lands $200 million upfront, with the potential for much more in clinical and regulatory milestones.
By Nicole Gray • May 18, 2016 -
Editas forges $5 million CRISPR research deal with Cystic Fibrosis Foundation
While Editas has no approved drugs yet, the promise and hope surrounding gene-editing has spurred several development deals.
By Nicole Gray • May 17, 2016 -
With generics deal pending, Teva's Europe portfolio attracts buyers
Novartis and Mylan are both reportedly interested in acquiring Teva's businesses in the U.K., Ireland, and Iceland.
By Ned Pagliarulo • May 16, 2016 -
Pfizer adds eczema drug in $5.2 billion deal for Anacor
Anacor's main drug candidate, crisaborole, is currently under FDA review for treatment of eczema.
By Ned Pagliarulo • May 16, 2016 -
Baxter reportedly top suitor for Indian injectables maker
But the Chinese conglomerate Fosun Group has also made an offer, according to The Economic Times.
By Ned Pagliarulo • May 12, 2016
Previous
